ASCO 2020 prostate cancer highlights

Bookmark and Share
Published: 10 Jun 2020
Views: 4458
Prof Karim Fizazi, Prof Axel Merseburger, Dr Kim Chi and Prof Amit Bahl

Prof Karim Fizazi (Institut Gustave Roussy, Paris, France) chairs a virtual discussion with Prof Axel Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany), Dr Kim Chi (BC Cancer Research Centre, Vancouver, Canada) and Prof Amit Bahl (University Hospitals Bristol, Bristol, UK) about the main prostate cancer highlights from ASCO 2020.

Prof Merseburger provides an overview of the latest developments presented around PSMA imaging. He outlines two prospective phase III trials that focus on the use of PSMA pet imaging prior to radical prostatectomy and in patients with biochemically recurrent prostate cancer.

Dr Chi explains the results of the randomised, phase II TheraP trial, which assessed the use of LuPSMA theranostic versus cabazitaxel in patients with metastatic castration resistant prostate cancer (mCRPC).

Prof Bahl comments that these results are exciting but will require further validation, most likely from the randomised phase III VISION trial. He also emphasises this data does not mean the end of chemotherapy use in prostate cancer, but the start of theranostics instead.

Prof Merseburger elaborates on the results of the phase III HERO trial, comparing relugolix (an oral GnRH receptor antagonist) versus leuprolide acetate for advanced prostate cancer.

The panel also discuss the practice-changing developments in non-metastatic castration resistant disease, including the ARAMIS, PROSPER and SPARTAN trials.

Dr Chi concludes by outlining the latest updates from the PROfound trial, which assessed health-related quality of life in patients receiving olaparib.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).